SEMAGLUTIDE 5MG (GLP-1) ANALOGUE

SKU
PN-SEMA-5
Rating:
100 % of 100
In stock
$149.99
  • Buy 5 for $134.99 each and save 10%
  • Buy 10 for $127.99 each and save 15%
  • Buy 20 for $119.99 each and save 20%
1499.9 Reward Points will be used to purchase this product

Buy this product and Earn 20.00 Pinnacle Points click here to login

-
+

BACTERIOSTATIC WATER

For this product you will need: BACTERIOSTATIC WATER For reconstitution.

Overview

The chemicals/materials for sale here are intended for laboratory and research use only, unless otherwise explicitly stated. They are not intended for human ingestion or for use in products that may be ingested. When you buy semaglutide it will ship as a freeze dried powder. To research this must reconstituted with bacteriostatic water which is available on on our site.

What Is SEMAGLUTIDE 5MG (GLP-1) ANALOGUE?

Semaglutide is a synthetic derivative of glucagon-like peptide-1 (GLP-1). It is an FDA-approved drug used for the management of type 2 diabetes. It has been shown to be safe and effective for weight loss and reducing cardiovascular risk. It also might be beneficial in improving lung function and Alzheimer’s disease.

Semaglutide was first designed in 2012 in order to make a GLP-1 analogue with a long half-life that is resistant to degradation. FDA first approved it under the brand name Ozempic in December 2017. In September 2019, oral semaglutide (Rybelsus) was approved for the treatment of type 2 diabetes in adults. Semaglutide for sale is available at Pinnacle Peptides to support your research.

Structure Of SEMAGLUTIDE 5MG (GLP-1) ANALOGUE

From Pubchem

 

Synonyms: Semaglutide, Ozempic, Rybelsus
Molecular Formula: C187H291N45O59
Molecular Weight: 4114 g/mol
CAS number: 910463-68-2
PubChem CID: 56843331

Mechanism Of SEMAGLUTIDE 5MG (GLP-1) ANALOGUE

Semaglutide is structurally similar to human GLP-1 with minor variations. It binds to GLP-1 receptors and mimics the physiological actions of glucagon-like peptide-1. It promotes insulin production and stimulates the synthesis of pancreatic beta cells responsible for insulin formation and release. Furthermore, it inhibits glucagon secretion that promotes gluconeogenesis (synthesis of glucose from non-carbohydrate sources) and glycogenolysis (breakdown of glycogen into glucose). Additionally, it reduces body fat, food intake and appetite.

Pre-Clinical/Clinical Research

1. Diabetes

FDA approved semaglutide after a series of successful trials called SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes). These trials played an important role in establishing the dose of semaglutide for type 2 diabetes. It is important to note that these trials are still ongoing and currently semaglutide is in phase 3.

The most recent SUSTAIN trial was published in 2022. It found that weekly administration of semaglutide led to a more substantial reduction in HbA1C levels when compared to thrice-daily insulin aspart. Additionally, individuals who received semaglutide treatment also experienced greater weight loss compared to those who were prescribed insulin aspart [1].

2. Weight Loss

Extensive research has been conducted on semaglutide's potential for inducing weight loss. In a 2018 study, the effect of baseline BMI and the occurrence of nausea and vomiting on semaglutide-induced weight loss was examined. The findings indicated that a higher baseline BMI was associated with significant weight loss, with no reports of nausea and vomiting. Furthermore, semaglutide showed greater weight loss effects compared to comparators, whether they received a placebo or other GLP-1 agonists, irrespective of their initial BMI [2].

In a subsequent study conducted over 52 weeks, semaglutide was found to be well-tolerated, with nausea being the most commonly observed side effect. When combined with lifestyle and dietary adjustments, semaglutide produced greater weight loss than a placebo [3]. Similarly, another study reported that overweight or obese adults who completed a 20-week lead-in period and continued semaglutide treatment experienced ongoing weight loss compared to those on placebo [4].

A literature review article published in 2023 summarized the outcomes of three clinical trials (SUSTAIN, PIONEER, and STEP) and investigated the weight loss effects of semaglutide. The review concluded that both oral and injectable forms of semaglutide exhibited superior efficacy in promoting weight loss compared to placebos and other medications. This success ultimately led to FDA approval of semaglutide for weight loss [5].

Summary

At present, two phase-three clinical trials, known as the Evoke trial and the Evoke plus trial, are underway to evaluate the effectiveness of semaglutide in early Alzheimer's disease [6]. Additionally, the SOUL and SELECT trials are ongoing to investigate cardiovascular outcomes in individuals with type 2 diabetes who are using semaglutide [7, 8]. At Pinnacle Peptides, the semaglutide purchase is limited to educational and research purposes. We encourage you to only buy semaglutide if you are a qualified researcher.

References

  1. Kellerer, M., et al., Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial. Diabetes Obes Metab, 2022. 24(9): p. 1788-1799.
  2. Ahrén, B., et al., Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, Obesity and Metabolism, 2018. 20(9): p. 2210-2219.
  3. Gao, X., et al., Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 2022. 13.
  4. Rubino, D., et al., Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021. 325(14): p. 1414-1425.
  5. Singh, G., M. Krauthamer, and M. Bjalme-Evans, Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management. Journal of Investigative Medicine, 2022. 70(1): p. 5-13.
  6. Atri, A., et al., evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer’s disease. Alzheimer's & Dementia, 2022. 18(S10): p. E062415.
  7. McGuire, D.K., et al., Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes, Obesity and Metabolism, 2023. 25(7): p. 1932-1941.
  8. Ryan, D.H., et al., Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J, 2020. 229: p. 61-69.

Certificate of Analysis (COA)

COA

High Performance Liquid Chromatography (HPLC)

HPLC

What is Semaglutide?

Semaglutide is a weight loss medication in the class of drugs known as GLP-1 receptor agonists. It is applied to the management of type 2 diabetes. Semaglutide mimics the actions of the GLP-1 hormone, a naturally occurring hormone that controls blood sugar levels. This weight loss peptide improves sensations of fullness by increasing insulin secretion, decreasing glucagon production, slowing stomach emptying, and activating the GLP-1 receptors. It has effectively lowered blood sugar levels, encouraged weight loss, and reduced the risk of cardiovascular events in people with type 2 diabetes. It is normally provided as a once-weekly injection.

Semaglutide Research

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug whose therapeutic effects in managing type 2 diabetes mellitus have been thoroughly investigated. The research on semaglutide is reviewed here, emphasizing its mechanisms of action, clinical efficacy, and related investigations.

Mechanisms of Action

The effects of semaglutide are brought about by activating the body's GLP-1 receptors. Semaglutide increases glucose-dependent insulin secretion decreases glucagon production, slows stomach emptying, and encourages satiety by acting similarly to the naturally occurring hormone GLP-1. These systems work together to help people with type 2 diabetes maintain their weight and glycemic control.

Clinical Efficacy

Glycemic Control:

Semaglutide has proven to be remarkably effective in decreasing blood sugar levels. According to clinical trials, using semaglutide improves long-term glycemic control by significantly lowering glycated hemoglobin (HbA1c) levels.

Semaglutide for Weight Loss:

Semaglutide has also demonstrated promise to aid in weight loss in those with type 2 diabetes. Clinical trials have repeatedly shown that patients taking this peptide have significant weight loss compared to those taking a placebo or another antidiabetic drug.

Cardiovascular Benefits:

Semaglutide's influence on cardiovascular outcomes in people with type 2 diabetes has been studied. According to studies, taking semaglutide lowers the risk of serious cardiovascular events such as myocardial infarction without death, stroke, and cardiovascular mortality.

Clinical Trials

SUSTAIN Trials:

The SUSTAIN clinical trial program evaluated Semaglutide's effectiveness and safety in people with type 2 diabetes. These studies showed that Semaglutide outperformed other GLP-1 RAs and oral diabetes medicines regarding glycemic management and weight loss.

PIONEER Trials:

The use of Semaglutide in various treatment regimes, including once-weekly and oral forms, was examined in the PIONEER trials. These studies proved Semaglutide's efficacy in multiple patient demographics and offered insightful information about its clinical uses.

SELECT Trials:

The SELECT clinical trial program's main objective was to assess the cardiovascular effects of Semaglutide use. These studies showed that people using Semaglutide had a lower risk of serious adverse cardiovascular events than those taking a placebo.

Where to Buy Semaglutide

If you want to purchase Semaglutide online, look at Pinnacle Peptides. Not only this peptide but other peptides are also available here. You can order a single product or bulk products and avail huge discounts. At present, Semaglutide for sale here is available in vials of 5MG at our online store. When you buy Semaglutide, you're acquiring a vital resource that has the potential to revolutionize your research.

Disclaimer

The products we offer are intended for laboratory research use only. In purchasing any of these items, the customer acknowledges the risks of consuming or distributing these products. These chemicals are NOT intended to use as food additives, drugs, cosmetics, household chemicals, or other inappropriate applications. Listing a material on this site does not constitute a license to its use in infringement of any patent. The products will be handled only by qualified and properly trained professionals. All customers represent and warrant that through their review and study, they are fully aware and knowledgeable about the following: Government regulations regarding the use of and exposure to all products—the health and safety hazards associated with handling the products they purchase. An adequate warning of any products' health and safety hazards is necessary. Pinnacle Peptides reserves the right to limit and deny sales of products to any unqualified individuals if we have reason to believe that misuse will occur.

Submit your review to Earn 50 Pinnacle Points click here to login

Write Your Own Review
You're reviewing:SEMAGLUTIDE 5MG (GLP-1) ANALOGUE
Your Rating
DISCLAIMER: The products sold on this site are not a drug nor is it intended to treat, diagnose, cure or prevent any disease, nor is it meant for ANY cosmetic purpose. Pinnacle Peptides makes no claims of alleged beneficial properties of any product on this site if injected or ingested in any manner. Our Peptides are exclusively distributed legally within the laws of safe harbor for research peptides and are to be used for that purpose ONLY. If any country’s governing bodies feel we are in violation of their laws regarding peptides, we ask you contact us immediately via [email protected] so we may expeditiously rectify the situation.All customers represent and warrant that through their own review and study that they are fully aware and knowledgeable about the following:Their government regulations regarding the importation, purchase, possession and use of peptides. The health and safety hazards associated with the handling of peptides in a research setting. That peptides are NOT intended to be used as a food additive, drug, vitamin, supplement, cosmetic or any other inappropriate application. Such a sale would be otherwise denied.
Catalog
Product List
Research Peptides
Research Chems
GLP-1 Peptides
Blends
Diluents